tbuckley/cabot-search huggingface dataset:
Reversal of GATA-6 Downregulation Promotes Smooth Muscle Differentiation and Inhibits Intimal Hyperplasia in Balloon-Injured Rat Carotid Artery
Authors: Toshiaki Mano, Zhengyu Luo, Slawomir L. Malendowicz, Todd Evans, Kenneth Walsh
Journal: Circulation Research (1999)

Abstract —The GATA-6 transcription factor is expressed in quiescent vascular smooth muscle cells (VSMCs) in culture, and levels of its transcript are rapidly downregulated on mitogen stimulation. In this study, we demonstrate that the GATA-6 transcript, protein, and DNA-binding activity are downregulated in rat carotid arteries on balloon injury. Downregulation was detected at 1 and 3 days after injury and recovered by 7 days. To assess the role of GATA-6 downregulation in injury-induced vascular lesion formation, adenoviral vectors were used to express wild-type human GATA-6 cDNA (Ad-GATA6) or an inactive mutant cDNA that lacks a portion of the zinc-finger domain (Ad-GATA6ΔZF). Adenovirus-mediated GATA-6 gene transfer to the vessel wall after balloon injury partially restored the levels of GATA-6 protein and DNA-binding activity to before injury levels. The local delivery of Ad-GATA6 but not Ad-GATA6ΔZF inhibited lesion formation by 46% relative to saline control and 50% relative to a control adenovirus that expressed lacZ . Local delivery of Ad-GATA6 also reversed changes in the expression patterns of smooth muscle myosin heavy chain, smooth muscle α-actin, calponin, vinculin, metavinculin, and proliferating cell nuclear antigen that are associated with injury-induced VSMC phenotypic modulation. These data indicate that the injury-induced downregulation of GATA-6 is an essential feature of VSMC phenotypic modulation that contributes to vessel lesion formation.
Colorectal Cancer Detection
Authors: Dennis L. Fowler
Journal: JAMA (1981)

<h3>To the Editor.—</h3> In a recent article Kurnick et al report a 7.5% incidence of carcinoma in patients who had positive results on Hemoccult slide tests used as a screening technique. However, to use that percentage as the endpoint in evaluating their screening program seems invalid for two reasons. First, no mention is made of the use of colonoscopy to examine these patients with blood in their stools. Two reports have documented that after normal findings at barium enema examination, a source of blood loss can be identified at the time of colonoscopy in about 20% of patients with occult blood and more than 40% of patients with frank blood in their stools.<sup>1,2</sup>Depending on the series, 25% to 30% of these lesions were carcinoma. The incidence of false-negative barium enema results is so great that Gilbertsen et al<sup>3</sup>use colonoscopy as the first diagnostic procedure in these patients and obtain a barium enema examination only when colonoscopy is incomplete. In their series of patients with positive results on the Hemoccult slide tests, 56 patients had a carcinoma of the colon above the reach of the
Persistence of antigen in nonarthritic joints.
Authors: A Fox, L E Glynn
Journal: Annals of the Rheumatic Diseases (1975)

The presence of antigen, IgG and C3 was shown by radioautography and immunofluorescence in the collagenous tissues of the joints of animals injected intra-articularly with antigen after having been previously immunized with that antigen in Freund9s incomplete adjuvant. Since these joints were shown to be virtually free of inflammatory reactions, we suggest that the persistence of immune complexes activating complement cannot fully explain the chronicity of experimental allergic arthritis.
Possible multicentric occurrence of hepatocellular carcinoma: A clinicopathological study
Authors: Kenji Takenaka, Eisuke Adachi, Takashi Nishizaki, Kaichiro Hiroshige, Toshihiko Ikeda, Masazumi Tsuneyoshi, Keizo Sugimachi
Journal: Hepatology (1994)

To assess the features of multicentric occurrence in hepatocellular carcinoma, we analyzed 10 of 72 patients (14%) who had undergone hepatic resection for hepatocellular carcinoma from May 1989 to October 1992 both clinically and pathologically. The multicentric occurrence of hepatocellular carcinoma was defined among the simultaneously detected small tumors as (a) at least one tumor consisting of extremely well-differentiated (grade I) hepatocellular carcinoma growing in a replacing pattern or (b) one of a group of hepatocellular carcinomas growing in an area of adenomatous hyperplasia. Of the 10 patients, the tumors in 9 were diagnosed as synchronous multicentric hepatocellular carcinomas, whereas the tumor in 1 was considered metachronous. All patients had cirrhosis; one of them had hepatitis B virus infection and nine patients had HCV infection. The inflammatory findings in the parenchyma were determined on the basis of serum enzyme values (AST, 89 +/- 27 IU/L; ALT, 96 +/- 43 IU/L). One or two tumors in 9 of 10 patients had thin trabecular or trabecular patterns showing replacing growth. In addition, one of the two tumors in two of nine patients was observed growing in areas of adenomatous hyperplasia. Recurrences were found in 4 of 10 patients. The 3-yr disease-free survival rate was 23%. Multiple recurrences were recognized in the two patients, and in the patients who underwent repeat surgery, grade I tumors were also found. Even though these tumors were small and well-differentiated, the recurrence rate was high. Therefore to detect the recurrence of metachronous multicentric hepatocellular carcinoma at an earlier stage, careful follow-up after surgery should be carried out.
Can available interventions end preventable deaths in mothers, newborn babies, and stillbirths, and at what cost?
Authors: Zulfiqar A Bhutta, Jai K Das, Rajiv Bahl, Joy E Lawn, Rehana A Salam, Vinod K Paul, M Jeeva Sankar, Hannah Blencowe, Arjumand Rizvi, Victoria B Chou, Neff Walker
Journal: The Lancet (2014)
800 SUSTAINED VIROLOGIC RESPONSE TO INTERFERON ALFA-2B PLUS RIBAVIRIN PREDICTS LONG-TERM CLEARANCE OF HCV IN PEDIATRIC PATIENTS AT 5 YEAR FOLLOW-UP
Authors: D. Kelly, B. Haber, R.P. Gonzalez-Peralta, K.F. Murray, M.M. Jonas, J.P. Molleston, M.R. Narkewicz, F.R. Sinatra, T. Lang, A. Lachaux, S. Wirth, M. Shelton, H.S. Te, H. Pollack, W. Deng, S. Noviello
Journal: Journal of Hepatology (2008)
Kidney Failure Rates End 20-Year Climb
Authors: M. Mitka
Journal: JAMA (2005)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Control of invasive pulmonary aspergillosis with oral itraconazole in a bone marrow transplant patient
Authors: David W. Denning, Daniel E. Stepan, Karl G. Blume, David A. Stevens
Journal: Journal of Infection (1992)

Pulmonary aspergillosis following bone marrow transplantation carries a mortality of 94%, irrespective of current treatment. We treated a patient who had acquired aspergillosis some 80 days after allogeneic bone marrow transplantation, with oral itraconazole, 600 mg daily. After initial deterioration, clinical and radiographic resolution occurred during 3 months of therapy despite severe graft-vs.-host and cytomegalovirus disease. Itraconazole should be considered for therapy of pulmonary aspergillosis in this and other immunocompromised settings.
Parkinson Disease in Twins&lt;SUBTITLE&gt;An Etiologic Study&lt;/SUBTITLE&gt;
Authors: Caroline M. Tanner
Journal: JAMA (1999)

The cause of Parkinson disease (PD) is unknown. Genetic linkages have been identified in families with PD, but whether most PD is inherited has not been determined.To assess genetic inheritance of PD by studying monozygotic (MZ) and dizygotic (DZ) twin pairs.Twin study comparing concordance rates of PD in MZ and DZ twin pairs.A total of 19842 white male twins enrolled in the National Academy of Sciences/National Research Council World War II Veteran Twins Registry were screened for PD and standard diagnostic criteria for PD were applied. Zygosity was determined by polymerase chain reaction or questionnaire.Parkinson disease concordance in twin pairs, stratified by zygosity and age at diagnosis.Of 268 twins with suspected parkinsonism and 250 presumed unaffected twin brothers, 193 twins with PD were identified (concordance-adjusted prevalence, 8.67/1000). In 71 MZ and 90 DZ pairs with complete diagnoses, pairwise concordance was similar (0.129 overall, 0.155 MZ, 0.111 DZ; relative risk, 1.39; 95% confidence interval, 0.63-3.1). In 16 pairs with diagnosis at or before age 50 years in at least 1 twin, MZ concordance was 1.0 (4 pairs), and DZ was 0.167 (relative risk, 6.0; 95% confidence interval, 1.69-21.26).The similarity in concordance overall indicates that genetic factors do not play a major role in causing typical PD. No genetic component is evident when the disease begins after age 50 years. However, genetic factors appear to be important when disease begins at or before age 50 years.
Calcium and Cardiac Arrest
Authors: MICHAEL C. FINN
Journal: Annals of Internal Medicine (1987)

Letters and Corrections1 April 1987Calcium and Cardiac ArrestMICHAEL C. FINN, M.D.MICHAEL C. FINN, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-106-4-630_2 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: During the past year the American Heart Association (1) has revised its recommendations concerning the use of calcium in patients with cardiac arrest. According to these guidelines, routine use of calcium during cardiac arrest and electromechanical dissociation is no longer advised. This recommendation is based on a number of retrospective and prospective studies in cardiac arrest that do not show clear-cut benefits from calcium (3, 4).A number of studies have shown adverse effects on the myocardium from excess calcium accumulation occurring during cardiopulmonary arrest. Stempein and associates (5) concluded that the administration of calcium during cardiopulmonary...References1. Standards and guidelines for cardiopulmonary resuscitation (CPR) of emergency cardiac care (ECC). JAMA. 1986;255:2905-89. CrossrefMedlineGoogle Scholar2. STEUVENTHOMPSONAPRAHAMIANDARIN HBCJ. Use of calcium in prehospital cardiac arrest. Ann Emerg Med. 1983;12:136-9. CrossrefMedlineGoogle Scholar3. STEUVENTHOMPSONAPRAHAMIAN HBC. Calcium chloride: reassessment of use in asystole. Ann Emerg Med. 1984;13:820. CrossrefMedlineGoogle Scholar4. HARRISONAMERY EB. Use of calcium in electro-mechanical dissociation. Ann Emerg Med. 1984;13:844. CrossrefMedlineGoogle Scholar5. STEMPEINKATZMESSINEO AAF. Calcium and cardiac arrest. Ann Intern Med. 1986;105:603-6. LinkGoogle Scholar1. STEMPIENKATZMESSINEO AAF. Calcium and cardiac arrest. Ann Intern Med. 1986;105:603-6. LinkGoogle Scholar2. STEUVENTHOMPSONAPRAHAMIANDARIN HBCJ. Use of calcium in prehospital cardiac arrest. Ann Emerg Med. 1983;12:136-9. CrossrefMedlineGoogle Scholar3. STEUVENTHOMPSONAPRAHAMIANTONSFELDTKASTENSON HBCDE. The effectiveness of calcium chloride in refractory electromechanical dissociation. Ann Emerg Med. 1985;14:626-9. CrossrefMedlineGoogle Scholar4. STEUVENTHOMPSONAPRAHAMIANTONSFELDTKASTENSON HBCDD. Lack of effectiveness of calcium chloride in refractory asystole. Ann Emerg Med. 1985;14:630-2. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Northshore Cardiovascular Associates Slidell, LA 70461 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByIs Calcium Beneficial or Deleterious in Patients with Cardiac Arrest?Arnold M. Katz, MD 1 April 1987Volume 106, Issue 4Page: 630-631KeywordsCalciumCardiac arrestHeartMyocardiumProspective studies Issue Published: 1 April 1987 PDF DownloadLoading ...
The use of bi-layer silk fibroin scaffolds and small intestinal submucosa matrices to support bladder tissue regeneration in a rat model of spinal cord injury
Authors: Yeun Goo Chung, Khalid Algarrahi, Debra Franck, Duong D. Tu, Rosalyn M. Adam, David L. Kaplan, Carlos R. Estrada, Joshua R. Mauney
Journal: Biomaterials (2014)
Single-Agent and Combination Therapeutic Strategies to Inhibit Hepatocyte Growth Factor/MET Signaling in Cancer
Authors: Luca Toschi, Pasi A. Jänne
Journal: Clinical Cancer Research (2008)

Abstract Receptor tyrosine kinases are often aberrantly activated in human malignancies and contribute to cancer development and progression. Specific receptor tyrosine kinase inhibitors have been shown to be clinically effective therapies in subsets of cancer patients with either hematologic or solid tumors. Activation of the hepatocyte growth factor (HGF)/MET signaling pathway has been found to play a critical role in oncogenesis, cancer metastasis, and drug resistance. These observations have led to the development of agents that can effectively inhibit HGF/MET signaling through direct inhibition of the receptor (anti-MET antibodies), through inactivation of its ligand HGF (AMG102, L2G7), by interfering with HGF binding to MET (NK4), or by inhibiting MET kinase activity (PHA-665752 and SU11274). Moreover, the combination of anti-MET therapeutic agents with either signal transduction inhibitors (ERBB family or mTOR inhibitors) or with cytotoxic chemotherapy has been evaluated in preclinical models. These studies provide insight into the rational development of combination therapeutic strategies that can be evaluated in clinical trials. This review will discuss different strategies of MET inhibition with a specific focus on combination therapeutic approaches.
448 Decline of HCV-specific CD8+ T cells during interferon-alpha therapy of acute hepatitis C (HCV): Role of apoptosis vs. differential regulation of chemokine receptors
Authors: J. Wiegand, H. Wedemeyer, A. Ciner, V. Schlaphoff, P. Buggisch, E. Jaeckel, M.P. Manns, M. Comberg
Journal: Journal of Hepatology (2006)
Ethics of New Reproductive Technologies: The Glover Report to the European Commission
Authors: Jon F. Watchko
Journal: JAMA (1990)

Debate regarding the appropriate use of new reproductive technologies (such as artificial insemination and in vitro fertilization) continues to broaden both in the United States and Europe. Many Western European countries have established national commissions to study the ethical and public policy issues related to these new "medical" techniques. The Benda Commission in West Germany, the Santosuosso Commission in Italy, and the Warnock Committee in the United Kingdom were organized for just this purpose. Similarly, the Commission of the European Community invited specialists under the chairmanship of Jonathan Glover to examine the ethical issues raised by the use of these new techniques of assisted reproduction. Their report constitutes the content of this book. The book itself has six major sections. The first chapter provides an overview of ethical theory and an approach to resolving the conflicts of interest that frequently attend the use of these new reproductive techniques. Chapters 2
Book Review Adolescent Health Care: A Practical Guide Fifth edition. Edited by Lawrence S. Neinstein, Catherine M. Gordon, Debra K. Katzman, David S. Rosen, and Elizabeth R. Woods. 1152 pp., illustrated. Philadelphia, Lippincott Williams &amp; Wilkins, 2008. $119. 978-0-7817-9256-1
Authors: Howard R. Spivak
Journal: New England Journal of Medicine (2008)
Abstract 1460: AKAP12 regulates melanoma tumor growth and metastasis
Authors: Elizabeth C. Finger, Alice Banh, Erinn B. Rankin, Marta Vilalta, Adam J. Krieg, Marianne Broome-Powell, Amato J. Giaccia
Journal: Cancer Research (2011)

Abstract Skin cancer, which accounts for at least half of all cancers in the United States, is predicted to affects 1 in 5 Americans in their lifetime. Melanoma, the most serious form of skin cancer, is also the leading cause of all skin cancer deaths. This study demonstrates that AKAP12 (SSeCKS, AKAP250, gravin), a hypoxia-inducible scaffold protein, is considerably increased at the protein and RNA level in melanoma cell lines. In addition, there is a significant increase in RNA expression in primary and metastatic tumors when compared to normal specimens, as well as patients with poor prognosis, as measured by diminished 5- year survival. AKAP12 functions to dock many kinases and signaling proteins that regulate cell adhesion, spreading and migration, including: PKC, Src and F-actin. Since these processes are critical for tumor cell metastasis, we hypothesize that AKAP12 could be a central regulator of cancer progression. Stable knockdown of AKAP12 in two melanoma cell lines demonstrate decreases in invasion, migration and clonogenic potential in vitro, as well reduced colony forming abilities in conditions requiring anchorage-independent growth in soft agar. In vivo studies in a metastatic model of melanoma demonstrate a statistically significant decrease in tumors within the lungs of the AKAP12 knockdown groups, highlighting the importance of AKAP12 in metastatic disease. An orthotopic model also demonstrates decreased primary tumor growth and metastatic potential in mice injected with AKAP12 knocked down cells. Additionally, changes in cell morphology characteristic of increased motility and invasiveness are seen in cells containing AKAP12 but not those in which it had been knocked down. While this scaffold protein has been found to act as a tumor suppressor in several tissue types (lung, colon, prostate), we have uncovered its novel oncogenic properties in metastatic melanoma. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 1460. doi:10.1158/1538-7445.AM2011-1460
Arthritis and Society: The Impact of Musculoskeletal Diseases
Authors: George E. Ehrlich
Journal: JAMA (1987)

This third volume on rheumatology in the series of Butterworths International Medical Reviews is, like the curate's egg, good in parts. It amplifies material available in a more sketchy form in other books (notably recent books on rehabilitation in arthritis) and provides new insights, as one would expect from any work associated with Nortin Hadler. His recent essays and books provoke discussion and provide legitimacy for areas long eschewed by many of his "scientifically" oriented colleagues. Barring the fortuitous discovery of the miracle drug that ends arthritis forever, consideration for the patient in the societal constellation must perforce play a major role in treatment strategy. In my recent book,<i>Rehabilitation Management of Rheumatic Conditions</i>, I attempted to adumbrate the needs of the patient and solutions from the standpoint of rehabilitation; Hadler and Dennis Gillings, by and large, approach the same topic from the discipline of clinical epidemiology. The first section,
Skin calcium-binding protein immunoreactivity in basal cell carcinoma
Authors: Y. MEROT, L. DIDIERJEAN, J.-H. SAURAT
Journal: British Journal of Dermatology (1983)

Skin calcium-binding protein (SCaBP) is a low molecular weight protein of unknown function which is localized in the cytoplasm of epidermal basal cells. We have examined SCaBP immunoreactivity in basal cell carcinoma (BCC) since BCC cells retain some of the characteristics of basal cells, including the capacity for proliferation and migration from the dermo-epidermal junction. We also examined immunoreactivity to basement membrane zone (BMZ) antigens (type IV collagen, laminin and bullous pemphigoid antigen) in BCC. We found that all BCC cells showed SCaBP immunoreactivity regardless of the histological type or position of the cells. BMZ antigens were expressed around tumourous buds, although bullous pemphigoid antigen may also present a cytoplasmic immunoreactivity. Our results suggest that SCaBP immunoreactivity is independent of the basal position of the cell, but may be related to the proliferative capacity and the undifferentiated state of the cell.
Purification and amino acid analysis of two human glioma-derived monocyte chemoattractants.
Authors: T Yoshimura, E A Robinson, S Tanaka, E Appella, J Kuratsu, E J Leonard
Journal: The Journal of Experimental Medicine (1989)

Two chemoattractants for human monocytes were purified to apparent homogeneity from the culture supernatant of a glioma cell line (U-105MG) by sequential chromatography on Orange A-Sepharose, an HPLC cation exchanger, and a reverse phase HPLC column. On SDS-PAGE gels under reducing or nonreducing conditions, the molecular masses of the two peptides glioma-derived chemotactic factor 1 and 2 were 15 and 13 kD, respectively. Amino acid composition of these molecules was almost identical, and differed from other cytokines that have been reported. The NH2 terminus of each peptide was apparently blocked. When tested for chemotactic efficacy, the peptides attracted approximately 30% of the monocytes added to chemotaxis chambers, at the optimal concentration of 10(-9) M. Potency and efficacy were comparable with that of FMLP, which is often used as a reference attractant. The activity was chemotactic rather than chemokinetic. In contrast to their interaction with human monocytes, the pure peptides did not attract neutrophils. These pure tumor-derived chemoattractants can now be compared with attractants produced by normal cells and evaluated for their biological significance in human neoplastic disease.
A sequential study of the relationship between faecal Klebsiella aerogenes and the common clinical manifestations of ankylosing spondylitis.
Authors: C J Eastmond, M Calguner, R Shinebaum, E M Cooke, V Wright
Journal: Annals of the Rheumatic Diseases (1982)

An 8-month sequential study at 4-weekly intervals of faecal Klebsiella aerogenes and clinical activity of ankylosing spondylitis is described. Similar frequencies of faecal K. aerogenes were found in the 44 patients and 36 healthy controls studied. Eighteen patients on 19 occasions had K. aerogenes cultured from their faeces, when the preceding specimen had been negative. Six (31.6%) of these occasions were associated with a deterioration in clinical state compared with a similar deterioration associated with only 17 (9.8%) of the remaining 174 faecal culture sequences (p less than 0.02). These results suggest that clinical deterioration in ankylosing spondylitis may be associated with the acquisition of faecal K. aerogenes.